2022 World Conference on Lung Cancer (ePosters)-EP03.01-016. The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration

Pdf Summary

The Canadian Small Cell Lung Cancer Database (CASCADE) is a multi-institutional real-world evidence collaboration that aims to generate robust data on small cell lung cancer (SCLC) in Canada. SCLC represents 15% of diagnosed lung cancers, but there is limited evidence to guide management upon relapse. Clinical trials are challenging due to the aggressive nature of the disease, urgency to begin therapy, high incidence of brain metastases, and comorbidities in affected patients.<br /><br />Real-world evidence plays a significant role in identifying the impact of therapies studied in controlled trials on patients seen in routine practice, informing treatment in settings with limited evidence, and supporting regulatory approvals of new therapies. CASCADE is one of the largest real-world evidence databases for SCLC, including data from eight academic institutions across Canada. With ongoing data collection and harmonization, CASCADE aims to capture detailed clinical information about SCLC patients treated in the real-world and contribute to multiple clinical, research, and regulatory questions.<br /><br />The database contains over 150 variables covering baseline demographics, staging information, treatment details, and outcomes for patients with SCLC. A descriptive analysis using data from the first three centers revealed a median overall survival (OS) of 19.8 months from the date of diagnosis. Data harmonization is underway for additional CASCADE sites.<br /><br />The study also provides baseline characteristics of the patients, including age, year of diagnosis, sex, smoking history, stage, and performance status. The results show that the majority of patients were diagnosed between 2011 and 2015, with a median age of 68. Among the patients, 48% were male, 59% had a smoking history, and 36% had limited stage disease.<br /><br />The study also provides information on staging investigations, sites of metastatic disease, and treatment received by the patients. PET scans were performed in 54% of the patients, and CNS staging was done using MRI/CT in 63% of the patients. The most common sites of metastatic disease were the liver, bone, and brain.<br /><br />In conclusion, CASCADE is a valuable resource for generating real-world evidence on SCLC in Canada. The database provides insights into the baseline characteristics, staging investigations, sites of metastatic disease, and treatment outcomes of SCLC patients. This information can guide clinical practice, research, and regulatory decisions in the management of SCLC.

Asset Subtitle

Sara Mieko Moore

Meta Tag

Speaker Sara Mieko Moore

Topic Epidemiology

Keywords

CASCADE

real-world evidence

SCLC

lung cancer

clinical trials

baseline demographics

treatment details

metastatic disease

PET scans

CNS staging